Segment Overview: Returning guest, Dr. Arthur Kavanaugh discusses the recent (Oct 2017) FDA approval of SIMPONI ARIA ® (golimumab) as the first and only fully-human anti-tumor necrosis factor (TNF)-alpha therapy delivered via a 30-minute infusion for the treatment of adults living with active psoriatic arthritis (PsA).
Guest: Dr. Arthur Kavanaugh, MD
Presenter: Neal Howard
Guest Bio: Dr. Kavanaugh is a Professor of Medicine at University of California San Diego and a lead investigator for Janssen Biotech. He earned his AB (biology) at the Massachusetts Institute of Technology in Cambridge, MA. He earned his MD (Medicine) at St. Louis University Medical School in St. Louis, MO. His research interests include innovative strategies for the treatment of patients with rheumatoid arthritis and other rheumatic diseases. Prognostic and predictive factors for outcomes in rheumatic diseases. Research program on innovative approaches to various immunologic diseases, particularly novel biologic therapies. His clinical focus are rheumatoid arthritis, psoriatic arthritis, lupus, vasculitis, and scleroderma.